Anthropic and Chai Discovery on AI-Accelerated Drug Development

Designing a promising molecule addresses only part of the work required to develop a medicine. In this interview, Chai Discovery describes computational molecule design, while Anthropic describes an ambition to support the broader research process, including clinical development, regulatory work and transfer to manufacturing.

The speakers locate delays across multiple stages, starting with deciding which biological target to pursue. Their proposed division of work explains why better molecular designs alone would not establish faster treatment delivery. Chai's goal of generating molecules ready for patients directly from a computer remains a hypothesis, and the interview does not demonstrate a shortened path to an approved medicine.

“China cannot run faster than AI.”

Josh

“You could have a single person using lots and lots of Claude and foundation models actually running a portfolio of early stage drug programs.”

Eric

“the tools are becoming more valuable than they've ever been before.”

Josh